CD274 and renal cell carcinoma: Another phase II trial in RCC that compared atezolizumab plus bevacizumab against sunitinib, displayed enhanced efficacy for the combination in PDL1-positive patients, while sunitinib monotherapy had better results in in patients with predominant angiogenesis markers [205].